share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K：外國發行人報告
SEC announcement ·  03/21 04:43
牛牛AI助理已提取核心訊息
RedHill Biopharma Ltd. has announced the postponement of its Extraordinary General Meeting of Shareholders, which was originally scheduled for March 20, 2024. The adjournment was due to the absence of the required legal quorum. The meeting has been rescheduled to take place the following day, March 21, 2024, at 3:00 p.m. Israel time at the company's office in Tel Aviv. This information was disclosed in a Form 6-K filing with the United States Securities and Exchange Commission. The Form 6-K is also incorporated by reference into the company's various Registration Statements on Form S-8 and Form F-3.
RedHill Biopharma Ltd. has announced the postponement of its Extraordinary General Meeting of Shareholders, which was originally scheduled for March 20, 2024. The adjournment was due to the absence of the required legal quorum. The meeting has been rescheduled to take place the following day, March 21, 2024, at 3:00 p.m. Israel time at the company's office in Tel Aviv. This information was disclosed in a Form 6-K filing with the United States Securities and Exchange Commission. The Form 6-K is also incorporated by reference into the company's various Registration Statements on Form S-8 and Form F-3.
RedHill Biopharma Ltd.宣佈推遲原定於2024年3月20日舉行的特別股東大會。休會是由於缺乏所需的法定人數。會議已改期爲第二天，即2024年3月21日以色列時間下午3點在該公司位於特拉維夫的辦公室舉行。該信息是在向美國證券交易委員會提交的6-K表格中披露的。6-K表格還以引用方式納入公司在S-8表格和F-3表格上的各種註冊聲明中。
RedHill Biopharma Ltd.宣佈推遲原定於2024年3月20日舉行的特別股東大會。休會是由於缺乏所需的法定人數。會議已改期爲第二天，即2024年3月21日以色列時間下午3點在該公司位於特拉維夫的辦公室舉行。該信息是在向美國證券交易委員會提交的6-K表格中披露的。6-K表格還以引用方式納入公司在S-8表格和F-3表格上的各種註冊聲明中。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。